Catalyst overview
Research summary
This catalyst tracks a Phase 2 update for ABCL635 in Moderate-to-severe vasomotor symptoms (VMS) or "hot flashes". The expected timing is based on the latest available company guidance and may change.
8/8/25- Initiated dosing w/ initial efficacy data in mid-2026. 11/06/25:- ABCL635 continues progressing through Ph1 trial; initial efficacy data still expected Mid-2026. 01/12/26:- Phase 2 portion of Ph1/2 trial dosing begun; topline results for both phases expected Q3 2026. 02/24/26:- Phase 2 portion initiation reiterated; topline Ph1/2 results still expected Q3 2026. 05/11/26:- Interim Ph1 SAD data positive; MAD blinded. Phase 2 VMS efficacy readout expected Q3 2026 (NCT07118891). 08/05/26:- Enrollment completed; Phase 2 top-line data expected August 2026. 08/10/26:- Ph2 topline results positive in NCT07118891; met endpoints; well tolerated; no serious AEs.
Verification
Confirm timing and program details against the company announcement or filing.